Timeframe | Pre-registration | Within 4 weeks of study entry | Once every 5 treatment days during radiation | N months following randomization +/−  4 weeks | Within 1 week of SREc | ||
---|---|---|---|---|---|---|---|
3 mo | 6 mo | 12 mo | |||||
Standard of care biopsy of a metastatic lesion or pathology review confirming metastatic cancer | X | Â | Â | Â | Â | Â | Â |
CBC with differential | Â | X | Â | X | X | X | X |
CMP | Â | X | Â | Â | Â | Â | Â |
Imaging studiesd | Â | X | Â | Xa | Xa | Xa | Xa |
History and physical | Â | X | Â | Xb | Xb | Xb | Xb |
Performance status | Â | X | Â | X | X | X | X |
Adverse Events evaluation (CTCAE v4.0) | Â | Â | X | X | X | X | X |
BPI short form | Â | X | X | X | X | X | X |
EQ-5D-5L | Â | X | Â | X | X | X | X |
Lesions Identification worksheet | Â | X | Â | Â | Â | Â | Â |